GlassScriptPhysician profile
Nickolas Albert Tomasic
NPI 1104875160
$5,552.30
in general payments reported to CMS, 2019-2025
32 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $914 · 2020: $268 · 2021: $677 · 2022: $2,098 · 2023: $789 · 2024: $684 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,595.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,595.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $1,450.86 | 2021-2024 | Urolift, Solesta |
| Astellas Pharma US INC | $886.39 | 2019-2024 | Xtandi, Myrbetriq |
| Janssen Biotech, INC. | $589.02 | 2019-2024 | Erleada |
| Pfizer INC. | $512.01 | 2019-2025 | |
| Abbvie INC. | $337.41 | 2019-2024 | Lupron Depot, Botox |
| Sumitomo Pharma America, INC. | $234.08 | 2023-2025 | Orgovyx, Gemtesa |
| Boston Scientific Corporation | $216.63 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $186.40 | 2019-2024 | |
| Myovant Sciences INC. | $148.54 | 2021-2022 | |
| Urovant Sciences INC | $107.90 | 2022 | |
| Coloplast Corp | $95.09 | 2020-2023 | Titan, Speedicath |
| Axonics, INC. | $93.15 | 2022-2023 | Axonics |
| Merck Sharp & Dohme LLC | $76.36 | 2022-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Novartis Pharmaceuticals Corporation | $66.22 | 2019-2025 | |
| Allergan, INC. | $63.32 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $55.05 | 2023-2024 | Prolaris |
| Progenics Pharmaceuticals, INC. | $53.61 | 2023-2024 | Pylarify |
| Dendreon Pharmaceuticals LLC | $46.02 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $36.63 | 2019-2020 | |
| Sagent Pharmaceuticals | $34.71 | 2019-2022 | |
| Metuchen Pharmaceuticals | $29.34 | 2019 | |
| Urogen Pharma, INC. | $24.86 | 2024 | |
| Biotissue Holdings INC. | $24.56 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $24.37 | 2019 | |
| Halozyme INC | $23.72 | 2023 | |
| Convatec INC. | $23.43 | 2021 | |
| Ferring Pharmaceuticals INC. | $22.60 | 2024 | Adstiladrin |
| Accord Healthcare, INC. | $21.68 | 2022 | |
| Endo USA, INC. | $21.21 | 2025 | Xiaflex |
| Therapeuticsmd, INC. | $16.48 | 2019 | |
| Hollister Incorporated | $16.21 | 2022 | |
| Mission Pharmacal Company | $14.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nickolas Tomasic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.